Structural alterations of chromosome 5 in twelve human prostate cancer cell lines

Cancer Genetics and Cytogenetics

Volumn 106, Issue 2, 1998, Pages 105-109

  Ozen, Mustafa ^a,c   Navone, Nora M ^a   Multani, Asha S ^a   Troncoso, Patricia ^b   Logothetis, Christopher J ^a   Chung, Leland W K ^d   C , A ^a   Pathak, Sen ^a,c  

^a Department of Cell Biology ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 5; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; GENETIC LINKAGE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 5; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

MUS MUSCULUS;

EID: 0032189808     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(98)00051-X     Document Type: Article

References (32)

1. Parker S., Tong T., Bolden S., Wingo P. Cancer statistics, 1997. CA-Cancer J Clin. 47:1997;5-27.
2. Isaacs J.T. Molecular markers for prostate cancer metastasis. developing diagnostic methods for predicting the aggressiveness of prostate cancer Am J Pathol. 150:1997;1511-1521.
3. Brothman A.R., Watson M.J., Zhu X., Williams B.J., Rohr L. Evaluation of 20 archival prostate tumor specimens by fluorescence in situ hybridization (FISH). Cancer Genet Cytogenet. 75:1994;40-44.
4. Massenkeil G., Oberhuber H., Hailemariam S., Sulser T., Diener P.A., Bannwart F., Schafer R., Schwarte-Waldhoff I. p53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res. 14:1994;2789-2794.
5. Carter B.S., Epstein J.L., Isaacs W.B. ras gene mutations in human prostate cancer. Cancer Res. 50:1990;6830-6832.
6. Buttyan R., Sawczuk I.S., Benson M.C., Siegal J.D., Olsson C.A. Enhanced expression of the c-myc proto-oncogene in high grade human prostate cancers. Prostate. 11:1987;327-337.
7. Berube N.G., Speeva M.D., Chevrette M. Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del(12)(q13). Cancer Res. 54:1994;3077-3081.
8. Isaacs W.B., Bova G.S., Morton R.A., Bussemakers M.J., Brooks J.D., Ewing C.M. Molecular biology of prostate cancer. Sem Oncol. 21:1994;514-521.
9. Navone N.M., Troncoso P., Pisters L.L., Goodrow T.L., Palmer J.L., Nichols W.W., von Eschenbach A.C., Conti C.J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 85:1993;1657-1669.
10. Eagle L., Yin X., Brothman A., Williams B., Atkin N., Prochownik E. Mutation of the MXI1 gene in prostate cancer. Nat Genet. 9:1995;249-255.
11. Dong J.T., Lamb P.W., Rinker-Schaeffer C.W., Vukanovic J., Ichikawa T., Isaacs J.T., Barrett J.C. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 268:1995;884-886.
12. Vogelstein B., Fearon E.R., Kern S.E., Hamilton S.R., Preisinger A.C., Nakamura Y., White R. Allelotype of colorectal carcinomas. Science. 244:1989;207-211.
13. Ozen M., Multani A.S., Chang S.M., von Eschenbach A.C., Chung L.W.K., Pathak S. Establishment of an in vitro cell model system to study human prostate carcinogenesis. involvement of chromosome 5 in early stages of neoplastic transformation Int J Oncol. 8:1996;883-888.
14. Zhau H.Y., Chang S.M., Chen B.Q., Wang Y., Zhang H., Kao C., Sang Q.A., Pathak S., Chung L.W.K. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA. 93:1996;15152-15157.
15. Navone N.M., Olive M., Ozen M., Davis R., Troncoso P., Tu S.M., Johnston D., Pollack A., Pathak S., von Eschenbach A.C., Logothetis C.J. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 3:1997;2493-2500.
16. Thalmann G.N., Anezims P.E., Chang S.M., Zhau H.E., Kim E.E., Hopwood V.L., Pathak S., von Eschenbach A.C., Chung L.W.K. Androgen-independent cancer progression and bone metasasis in the LNCaP model of human prostate cancer. Cancer Res. 54:1994;2577-2581.
17. Pathak S. Chromosome banding techniques. J Reprod Med. 17:1976;25-28.
18. Brothman A.R., Lesho L.J., Somers K.D., Schellhammer P.F., Ladaga L.E., Merchant D.J. Cytogenetic analysis of four primary prostatic cultures. Cancer Genet Cytogenet. 37:1989;241-248.
19. Narayan P., Dahiya R. Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). J Urol. 148:1992;1600-1604.
20. Loop S.M., Rozanski T.A., Ostenson R.C. Human primary prostate cancer cell line, ALVA-31. a new model for studying the hormonal regulation of prostate tumor cell growth Prostate. 22:1993;93-108.
21. Degeorges A., Hoffschir F., Cussenot O., Gauville C., Le Duc A., Dutrillaux B., Calvo F. Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line. Int J Cancer. 15:1995;724-731.
22. Cook C.J., Bae V., Edelman W., Brothman A., Ware J. Cytogenetic characterization of the human prostate cancer cell line P69SV40T and its novel tumorigenic sublines M2182 and M15. Cancer Genet Cytogenet. 87:1996;14-23.
23. Nagarajan L., Zhao L., Lu X., Warrington J.A., Wasmuth J.J., Siciliano M.J., Deisseroth A.B., Liang J.C. 5q- chromosome. evidence for complex interstitial breaks in a case of refractory anemia with excess blasts Cancer Genet Cytogenet. 74:1994;8-12.
24. Ewing C.M., Ru N., Morton R.A., Robinson J.C., Wheelock M.J., Johnson K.R., Barrett J.C., Isaacs W.B. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells. correlation with re-expression of alpha catenin and restoration of E-cadherin function Cancer Res. 55:1995;4813-4817.
25. Groden J., Thliveris A., Smowitz W., Carlson M., Gelbert L., Albertsen H., Stevens J., Spirio L., Robertson M., Sargeant L., Krapcho K., Wolff E., Burt R., Hughes J.P., Warrington J., McPherson J., Wasmuth J., Paslier D., Abderrahim H., Cohen D., Leppert M., White R. Identification and characterization of the familial adenamatous polyposis coli gene. Cell. 66:1991;589-600.
26. Horii A., Nakatsuru S., Miyoshi Y., Ichii S., Nagase H., Ando H., Yanagisawa A., Nakamura Y. The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res. 52:1992;3231-3233.
27. Horii A., Nakatsuru S., Miyoshi Y., Ichii S., Nagase H., Ando H., Yanagisawa A., Tsuchiya E., Kato Y., Nakamura Y. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res. 52:1992;6696-6698.
28. Phillips S.M., Morton D.G., Lee S.J., Wallace D.M., Neoptlemos J.P. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q, and 16q in human prostate cancer. Br J Urol. 73:1994;390-395.
29. Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F. Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer. 21:1978;274-281.
30. Gibas Z., Becher R., Kawinski E., Horoszewicz J., Sandberg A.A. A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP). Cancer Genet Cytogenet. 11:1984;399-404.
31. Cher M.L., Bova G.S., Moore D.H., Small E.J., Carroll P.R., Pin S.S., Epstein J.I., Isaacs W.B., Jensen R.H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56:1996;3091-3102.
32. Visakorpi T., Kallioniemi A.H., Syvanen A.C., Hyytinen E.R., Karhu R., Tammela T., Isola J.J., Kallioniemi O.P. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55:1995;342-347.